PTAB Denies Request to Cross-Examine Experts Because Declarations Were Prepared for Other Proceedings and Were Not “Critical” Evidence

Nov 7, 2018

Reading Time : 1 min

Under 37 C.F.R. § 42.51(b)(1)(ii), “[c]ross examination of affidavit testimony prepared for the proceeding is authorized within such time period as the Board may set” (emphasis added). Nestlé argued that, even though the declarations were not prepared for the IPR proceeding, Steuben should produce the witnesses for deposition because the “declarations were recently created, and . . . Patent Owner has not asserted that the Declarants are unavailable,” citing IBG LLC et al. v. Trading Technologies Internationale, Inc., CBM2015-00179, Paper 39 (PTAB Apr. 15, 2016). The Board rejected that argument and distinguished the IBG case. In IBG, the Board ordered the petitioner to produce a witness from a prior litigation because the witness’s testimony “was the sole evidence that a reference was prior art.”  Here, Nestlé “d[id] not allege that Patent Owner’s evidence rises to such a critical level.”

The Board did not reach Nestlé’s alternative request to exclude the declarations because Nestlé had not filed a motion to exclude.

Practice Tip:  When seeking to cross-examine witnesses based on declarations from prior or parallel proceedings, parties should include in their requests an explanation of why the declaration is “critical” evidence in the IPR. Parties should also consider objecting to the declarations by filing a motion to exclude that includes a reasoned explanation justifying exclusion.

Nestlé Healthcare Nutrition, Inc. v. Steuben Food, Inc., IPR2015-00249, Paper 107 (PTAB Oct. 29, 2018).

Share This Insight

Previous Entries

IP Newsflash

March 12, 2026

The Northern District of Illinois recently dismissed a complaint without prejudice for failing to plausibly allege patent infringement. The court found that the allegations of direct infringement were insufficiently pled where the images of the accused product included in the complaint did not appear to show a particular necessary element of the claims.

...

Read More

IP Newsflash

March 12, 2026

The District of New Jersey recently denied the litigants’ request for a briefing schedule to resolve a dispute about a proposed discovery confidentiality order, and also denied extending the deadlines for the defendants’ invalidity and non-infringement contentions. At issue was the scope of the FDA and patent prosecution bars in the confidentiality order.

...

Read More

IP Newsflash

February 27, 2026

The USPTO Director denied a patent owner’s request for discretionary denial of two inter partes review (IPR) petitions, citing the petitioner’s “well-settled expectation” that it would not be accused of infringing the two challenged patents. The Director’s conclusion was based on the petitioner’s decade-long business relationship with the original owner of the challenged patents.

...

Read More

IP Newsflash

February 24, 2026

The Southern District of Florida recently dismissed a complaint without prejudice because the allegations used a form of “shotgun pleading.” The court explained that a shotgun pleading includes those where every count incorporates every preceding paragraph into each cause of action, and that dismissal of such pleadings was required under Eleventh Circuit precedent.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.